The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...